The Role of Vascular Endothelial Growth Factor As a Prognostic and Clinicopathological Marker in Osteosarcoma: a Systematic Review and Meta-analysis

Overview

Journal J Orthop Surg Res

Publisher Biomed Central

Specialty Orthopedics

Date 2021 Dec 29

PMID 34963495

Citations 8

Authors

Chao Zhang

Lin Wang

Chuang Xiong

Runhan Zhao

Hao Liang

Xiaoji Luo

Affiliations

Soon will be listed here.

Abstract

Background: In recent years, numerous investigations have been conducted to determine the clinical significance and critical functions of vascular endothelial growth factor (VEGF) in various malignant cancers. The purpose of this meta-analysis was to comprehensively evaluate the prognostic and clinicopathological value of VEGF in patients with osteosarcoma.

Methods: We performed a systematic literature retrieval of available databases. Odds ratios (ORs) or standard mean difference (SMD) for clinicopathological parameters, hazard ratios (HRs) for overall survival and disease-free survival were calculated to assess the correlation between VEGF expression and prognosis in patients with osteosarcoma.

Results: A total of 22 studies with 1144 patients were included in our study. Pooled analyses showed that VEGF overexpression predicted worse overall survival (HR, 2.42; 95% CI, 1.87-3.11, p < 0.001) and disease-free survival (HR, 2.604; 95% CI, 1.698-3.995, p < 0.001), respectively. Furthermore, investigation regarding osteosarcoma clinicopathologic characteristics suggested that high VEGF expression was significantly associated with metastasis (OR, 4.39; 95% CI, 2.77-6.95; p < 0.001), clinical stage (OR, 0.73; 95% CI, 0.62-0.87; p < 0.001), and microvessel density (SMD, 3.33, 95% CI,1.57-5.10, p < 0.001), but not associated with tumor location, gender, age, local recurrence, and chemotherapy response.

Conclusion: Our meta-analysis findings suggest that elevated VEGF expression may be a predictive biomarker for poor prognosis and adverse clinicopathological characteristics in patients with osteosarcoma.

Citing Articles

Prognostic Significance of Microvessel Density and Hypoxic Markers in Canine Osteosarcoma: Insights into Angiogenesis and Tumor Aggressiveness.

Gola C, Massimini M, Morello E, Maniscalco L, Conti L, Romanucci M Animals (Basel). 2024; 14(22).

PMID: 39595235 PMC: 11591178. DOI: 10.3390/ani14223181.

CCL2-CCR2 Axis Inhibition in Osteosarcoma Cell Model: The Impact of Oxygen Level on Cell Phenotype.

Petrosiute A, Musvicaite J, Petroska D, Scerbaviciene A, Arnold S, Matuliene J J Cell Physiol. 2024; 240(1):e31489.

PMID: 39587819 PMC: 11747949. DOI: 10.1002/jcp.31489.

Proteomic and transcriptomic analyses identify apo-transcobalamin-II as a biomarker of overall survival in osteosarcoma.

Lacinski R, Dziadowicz S, Roth C, Ma L, Melemai V, Fitzpatrick B Front Oncol. 2024; 14:1417459.

PMID: 39493449 PMC: 11527601. DOI: 10.3389/fonc.2024.1417459.

: NF-κB Inhibition as an Alternative to Overcome Osteosarcoma Heterogeneity.

Medeiros M, Guenka S, Bastos D, Oliveira K, Brassesco M Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931401 PMC: 11206879. DOI: 10.3390/ph17060734.

Exploration in the Mechanism of Ginsenoside Rg5 for the Treatment of Osteosarcoma by Network Pharmacology and Molecular Docking.

Liu M, Jiang D, Zhao X, Zhang L, Zhang Y, Liu Z Orthop Surg. 2023; 16(2):462-470.

PMID: 38086608 PMC: 10834211. DOI: 10.1111/os.13971.

References

Liu Y, Zhang F, Zhang Z, Wang D, Cui B, Zeng F . High expression levels of Cyr61 and VEGF are associated with poor prognosis in osteosarcoma. Pathol Res Pract. 2017; 213(8):895-899. DOI: 10.1016/j.prp.2017.06.004. View

Abdeen A, Chou A, Healey J, Khanna C, Osborne T, Hewitt S . Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer. 2009; 115(22):5243-50. PMC: 7251638. DOI: 10.1002/cncr.24562. View

Mirabello L, Troisi R, Savage S . Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009; 115(7):1531-43. PMC: 2813207. DOI: 10.1002/cncr.24121. View

Zong S, Li H, Shi Q, Liu S, Li W, Hou F . Prognostic significance of VEGF-C immunohistochemical expression in colorectal cancer: A meta-analysis. Clin Chim Acta. 2016; 458:106-14. DOI: 10.1016/j.cca.2016.04.037. View

Oda Y, Yamamoto H, Tamiya S, Matsuda S, Tanaka K, Yokoyama R . CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol. 2006; 19(5):738-45. DOI: 10.1038/modpathol.3800587. View

Jung S, Moon E, Seo H, Kim J, Kim G, Kim Y . Expression and significance of TGF-beta isoform and VEGF in osteosarcoma. Orthopedics. 2005; 28(8):755-60. DOI: 10.3928/0147-7447-20050801-11. View

Becker R, Galia C, Morini S, Viana C . Immunohistochemical expression of vegf and her-2 proteins in osteosarcoma biopsies. Acta Ortop Bras. 2014; 21(4):233-8. PMC: 3862008. DOI: 10.1590/S1413-78522013000400010. View

Lugowska I, Wozniak W, Klepacka T, Michalak E, Szamotulska K . A prognostic evaluation of vascular endothelial growth factor in children and young adults with osteosarcoma. Pediatr Blood Cancer. 2011; 57(1):63-8. DOI: 10.1002/pbc.23021. View

Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-6. DOI: 10.1056/NEJM197111182852108. View

10.

Lei P, Ding D, Xie J, Wang L, Liao Q, Hu Y . Expression profile of Twist, vascular endothelial growth factor and CD34 in patients with different phases of osteosarcoma. Oncol Lett. 2015; 10(1):417-421. PMC: 4487166. DOI: 10.3892/ol.2015.3246. View

11.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg. 2021; 88:105906. DOI: 10.1016/j.ijsu.2021.105906. View

12.

Lee Y, Tokunaga T, Oshika Y, Suto R, Yanagisawa K, TOMISAWA M . Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer. 1999; 35(7):1089-93. DOI: 10.1016/s0959-8049(99)00073-8. View

13.

Cerdeira A, Rajakumar A, Royle C, Lo A, Husain Z, Thadhani R . Conversion of peripheral blood NK cells to a decidual NK-like phenotype by a cocktail of defined factors. J Immunol. 2013; 190(8):3939-48. PMC: 3742368. DOI: 10.4049/jimmunol.1202582. View

14.

Weis S, Cui J, Barnes L, Cheresh D . Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol. 2004; 167(2):223-9. PMC: 2172541. DOI: 10.1083/jcb.200408130. View

15.

Azzi S, Hebda J, Gavard J . Vascular permeability and drug delivery in cancers. Front Oncol. 2013; 3:211. PMC: 3744053. DOI: 10.3389/fonc.2013.00211. View

16.

Wheeler K, Jena M, Pradhan B, Nayak N, Das S, Hsu C . VEGF may contribute to macrophage recruitment and M2 polarization in the decidua. PLoS One. 2018; 13(1):e0191040. PMC: 5764356. DOI: 10.1371/journal.pone.0191040. View

17.

Lammli J, Fan M, Rosenthal H, Patni M, Rinehart E, Vergara G . Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma. Int Orthop. 2012; 36(11):2307-13. PMC: 3479297. DOI: 10.1007/s00264-012-1629-z. View

18.

Tawbi H, Burgess M, Bolejack V, Van Tine B, Schuetze S, Hu J . Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017; 18(11):1493-1501. PMC: 7939029. DOI: 10.1016/S1470-2045(17)30624-1. View

19.

Baptista A, Camargo A, Filippi R, Oliveira C, de Azevedo Neto R, de Camargo O . Correlation between the expression of vegf and survival in osteosarcoma. Acta Ortop Bras. 2014; 22(5):250-5. PMC: 4199641. DOI: 10.1590/1413-78522014220500978. View

20.

Sadykova L, Ntekim A, Muyangwa-Semenova M, Rutland C, Jeyapalan J, Blatt N . Epidemiology and Risk Factors of Osteosarcoma. Cancer Invest. 2020; 38(5):259-269. DOI: 10.1080/07357907.2020.1768401. View